Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological disorder such as endometriosis, uterine fibroids, postoperative peritoneal adhesions, dysfunctional bleeding (metrorrhagia, menorrhagia) and dysmenorrhea; b) for the prevention of gynecological disorders such as postoperative, peritoneal adhesions, dysfunctional uterine bleeding (metrorrhagia, menorrhagia) and dysmenorrhea; and c) a method of treatment and prevention of the above mentioned disorders in a female, preferably in a human female, in need of treatment or prevention of one or more of these disorders, with an effective amount of a mesoprogestin. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiprogestins. The daily dose of mesoprogestin is 0.5 to 100 mg, preferably 5.0 to 50 mg and most preferably 10 to 25 mg. J867, J912, J956 and J1042 are the mesoprogestins preferred according to the invention.
1. A method for the treatment of endometriosis or uterine fibroids in a human female patient who desires to maintain pregnancy, comprising administering to the patient in need thereof an effective amount of at least one mesoprogestin selected from the group consisting of J867, J912, and J956, wherein the daily dose of mesoprogestin is 0.5 to 50 mg, and wherein the treatment is effected with much reduced abortifacient activity compared to RU 486.
2. A method according to claim 1 , wherein the method is for treating endometriosis.
3. The method of claim 1 , wherein the daily dose of mesoprogestin is 5.0 to 50 mg.
4. The method of claim 2 , wherein the daily dose of mesoprogestin is 5.0 to 50 mg.
5. The method of claim 1 , wherein the daily dose of mesoprogestin is 10 to 25 mg.
6. The method of claim 2 , wherein the daily dose of mesoprogestin is 10 to 25 mg.
7. The method of claim 1 , wherein the mesoprogestin is J867.
8. The method of claim 2 , wherein the mesoprogestin is J867.
9. The method of claim 1 , wherein the mesoprogestin is J912.
10. The method of claim 2 , wherein the mesoprogestin is J912.
11. The method of claim 1 , wherein the mesoprogestin is J956.
12. The method of claim 2 , wherein the mesoprogestin is J956.
13. The method of claim 1 , wherein the method is for treating uterine fibroids.
14. The method of claim 3 , wherein the method is for treating uterine fibroids.
15. The method of claim 5 , wherein the method is for treating uterine fibroids.
16. The method of claim 13 , wherein the mesoprogestin is J867.
17. The method of claim 14 , wherein the mesoprogestin is J867.
18. The method of claim 15 , wherein the mesoprogestin is J867.
19. The method of claim 1 , wherein the at least one mesoprogestin is the sole active agent administered to the patient for the treatment.
20. The method of claim 3 , wherein the at least one mesoprogestin is the sole active agent administered to the patient for the treatment.
21. The method of claim 13 , wherein the at least one mesoprogestin is the sole active agent administered to the patient for the treatment.
22. The method of claim 1 , wherein the treatment is effected without producing estrogen deficiency effects.